NTI

2.99%

6.9¢ neurotech international limited

Ann: Quarterly Report and Appendix 4C, page-28

First 28 Last

Share
Profile

Follow
bruutz82

1,528 Posts.

89

03/05/18

22:05

Post #: 32872717
Share
Originally posted by kickit2me ↑

Ok. So help me with this then.....

Seems I need a "little lesson".

Here is the clinical trial outline linked to from the NTI Clinical Trial Update 8th January:
https://clinicaltrials.gov/ct2/show/study/NCT02773303?term=Mente&rank=2

It says the trial's aims are:

This project aims:

to further explore the effectiveness of a novel sonified Neurofeedback management therapy for children diagnosed with Autism Spectrum Disorder (ASD)

to determine if balance control is different before and after therapy

And then the report presented at Cambridge Uni and summarised by NTI:

http://www.aspecthuntley.com.au/doc...Jyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true

Says there were positive changes in neurological function.

BUT ... what neurological function?

The study was about balance control - not about Austism. (Not surprising because Dr Carrick is ..."known for establishing the chiropractic neurology subspecialty" and chiropractors would tend to be interested in balance.)

So I'm a bit puzzled. It seems the clinical study looks to have demonstrated improved balance control but nothing about Autism (or APD).

Help me out here please.

Expand

The mCTSIB test is a neurological test that can determine (measure) the effect of neurological disorder to brain / ear and is utilsed pre post treatment to further determine the effectiveness neurological treatnent. So it is a test to measure only one element of neurological dysfunction among many other neasures NTI will utilise in the study
NTI Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

There are more pages in this discussion • 12 more messages in this thread...

First 28 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 6.9¢		Change 0.002(2.99%)		Mkt cap ! $64.55M

Open	High	Low	Value	Volume
6.7¢	7.2¢	6.7¢	$45.29K	648.2K

Buyers (Bids)

No.	Vol.	Price($)
3	684701	6.6¢

Sellers (Offers)

Price($)	Vol.	No.
6.9¢	100000	1

View Market Depth

No.	Vol.	Price($)
4	589299	0.070
1	36231	0.069
5	240000	0.068
2	255000	0.067
3	262000	0.066

Price($)	Vol.	No.
0.072	100000	1
0.074	40000	1
0.075	738582	2
0.076	90000	1
0.077	190000	3

Last trade - 15.37pm 22/11/2024 (20 minute delay)

NTI (ASX) Chart

Ann: Quarterly Report and Appendix 4C, page-28

Sales growth pushes Lovisa's fortunes (and shares) upwards

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Report and Appendix 4C, page-28

Top Stories

Sales growth pushes Lovisa's fortunes (and shares) upwards

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News